Browse > Article
http://dx.doi.org/10.5352/JLS.2008.18.4.494

Immunotoxicity Study of Separated Antigen from Helicobacter pylori.  

Park, Chang-Ho (Daegu Bio Industry Center)
Bae, Man-Jong (Dept. of Herbal Foodceutical Science, Daegu Haany University)
Publication Information
Journal of Life Science / v.18, no.4, 2008 , pp. 494-502 More about this Journal
Abstract
The anaphylaxis shock reaction on the whole cells of H. pylori exhibited a symptom of slight illness for the first and second medication of causing antigen at an antigen concentration of WC (H) $60\;{\mu}g/100\;{\mu}l$ for WC (H) and no anaphylaxis shock symptom was observed at an antigen concentration of $20\;{\mu}g/100\;{\mu}l$ for WC (L). In the case of anaphylaxis shock reaction on the crude urease, no symptom was observed at an antigen concentration of $20\;{\mu}g/100\;{\mu}l$ for both urease (L) and urease (H). In the heterologous passive cutaneous anaphylaxis (PCA) test using a guinea pig-rat, no positive reaction was detected in all the medication groups of WC (H), WC (L), urease (H) and urease (L). In the skin sensitization test, it was observed that the best antigen concentration not causing skin disorder at each of $80\;{\mu}g/100\;{\mu}l$, $40\;{\mu}g/100\;{\mu}l$, $20\;{\mu}g/100\;{\mu}l$, and $20\;{\mu}g/100\;{\mu}l$ was $40\;{\mu}g/100\;{\mu}l$.
Keywords
Adjuvant; immunotoxicity; anaphylaxis; heterologous passive cutaneous anaphylaxis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Parsonnet, J., R. A. Harris, H. M. Hack and D. K. Owens. 1996. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer; A mandate for clinical trials. Lancet 348, 150-154   DOI   ScienceOn
2 Ruggiero, P., P. Samuele, R. Rino and D. G. Giuseppe. 2003. The quest for a vaccine against Helicobacter pylori: How to move from mouse to man? Micro. Infec. 5, 749-756   DOI   ScienceOn
3 Rupnow, M. F., D. K. Owens, R. Shachter and J. Parsonnet. 1999. Helicobacter pylori vaccine development and use: A cost-effectiveness analysis using the institute of Medicine methodology. Helicobacter 4, 272-280   DOI   ScienceOn
4 Rupnow, M. F., R. D. Shachter, D. K. Owens and J. Parsonnet. 2001. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 20, 879-885   DOI   ScienceOn
5 Satoh, K., K. Kimura and Y. Taniguchi. 1996. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. Am. J. Gastroenterol 91, 963-969
6 Simon, P. M., P. L. Goode, A. Mobasseri and D. Zopf. 1997. Inhibition of Helicobacter pylori binding to gastrointestinal infect. Immun. 65, 750-757
7 Warren, J. R. and B. Marshall. 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 4, 1273-1275
8 IARC working group on the evaluation of carcinogenic risks to humans. 1994. Helicobacter pylori. in: Schistosomes, liver flukes, and Helicobacter pylori: views and expert opinions of IARC working group on the evaluation of carcirogenic risks to humans. Lyon: IARC Monogr Eval Carcinog Risks Hum. 61-241
9 Jo, E. H., S. D. Cho, N. S. Ahn, J. W.Jung, S. R. Yang, J. S. Park, K. S. Park, I. S. Hong, M. S. Seo, N. B. Tiep, Y. S. Lee and K. S. Kang. 2003. Antigenicity study of nonspecific immunostimulator $BARODON^{{\circledR}}$. Kor. J. Vet. Res. 43, 255-261
10 Marshall, B. J. and J. R. Warren. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 323, 1311-1315   DOI   ScienceOn
11 Megraud, F. 1998. Antibiotic resistance in Helicobacter pylori infection. Br. Med. Bull. 24, 207-216
12 Michetti, P., I. Corthésy-Theulaz, C. Davin, R. Haas, A. C. Vaney, M. Heitz, J. Bille, J. P. Kraehenbuhl, E. Saraga and A. L. Blum. 1994. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 107, 1002-1011   DOI
13 Blanchard, T. G., J. C. Eisenberg and Y. Matsumoto. 2004. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 22, 888-897   DOI   ScienceOn
14 Garhart, C. A., R. W. Redline, J. G. Nedrud and S. J. Czinn. 2002. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun. 3529-3538
15 Graham, D. Y., H. M. Malaty, D. G. Evans, D. J. Jr Evans, P. D. Klein and E. Adam. 1991. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100, 1495-1501   DOI
16 Hunt, R. H. 1996. Eradication of Helicobacter pylori infection. Am. J. Med. 100 (5A) 42S-50S   DOI   ScienceOn
17 Hayashi, K., T. Ishikawa, T. Yamashita, T. Tajima and K. Nakayama. 2003. Biphasic response of cutaneous blood flow induced by passive cutaneous anaphylaxis in rats. Eur. J. Pharmacol. 482, 305-311   DOI   ScienceOn
18 Hifumi, E., Y. Yamada and T. Uda. 2006. A catalytic antibody heavy chain HpU-2 degrading its epitope peptide and H. pylori Urease. Immunol. Lett. 103, 68-74   DOI   ScienceOn
19 Hu, L. T. and H. L. Mobley. 1990. Purification and N-Terminal analysis of urease from Helicobacter pylori. Infect. Immun. 58, 992-998
20 Kim, B. J., B. H. Kang, T. Y. Kim, T. H. Kim and K. W. Kim. 1997. Production and characterization of IgY specific to Helicobacter pylori. Kor. J. Appl. Microbiol. Biotechnol. 25, 612-616
21 Mabe, K., M. Yamada, I. Oguni and T. Takahashi. 1999. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob Agents Chemother. 43, 1788-1791
22 Justine, S. G., E. C. Natalie and H. S. Dieter. 1980. Methods in immunology, a laboratory text for instruction and research. W. A. Benjamin, Inc, Canada
23 Lee, D. H. 2002. Current status and treatment of Helicobacter pyri infection in korea. Kor. J. Gastrol. 39, 153-160
24 Lesley, E., M. J. Smythies, K. B. Novak, J. Waites, L. Russell, D. M. Casey and D. S. Phillip. 2005. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23, 901-909   DOI   ScienceOn
25 Ermak, T. H., P. J. Giannasca, R. Nichols, G. A. Myers, J. Nedrud, R. Weltzin, C. K. Lee, H. Kleanthous and T. P. Monath. 1998. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II- restricted responses. J. Exp. Med. 188, 2277-2288   DOI   ScienceOn
26 Birmingham, N., S. Payankaulam, S. Thanesvorakul, B. Stefura, K. HayGlass and V. Gangur. 2003. An ELISAbased method for measurement of food-specific IgE antibody in mouse serum: an alternative to the passive cutaneous anaphylaxis assay. J. Immunol. Methods 275, 89-98   DOI   ScienceOn